IP Library Patent Application 16564209
Patent Application
App. No. 16/564,209

ANTI-NUCLEAR ANTIBODY DETECTION AND DIAGNOSTICS FOR SYSTEMIC AND NON-SYSTEMIC AUTOIMMUNE DISORDERS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/564,209
Abstract

Provided are compositions that contain mammalian cells for use in detecting antibodies. The mammalian cells are modified such that they do not contain LEDGF protein. The mammalian cells are immobilized on a solid substrate. The compositions can also contain mammalian cells that contain the LEDGF protein. Methods for using the cell compositions in diagnostic approaches are included, as are kits for performing diagnostic tests.

Claims (13)

1 - 9 . (canceled)

10 . A method for determining whether a biological sample comprises antibodies that bind to LEDGF protein (anti-LEDGF Abs), the method comprising:

i) exposing the biological sample to mammalian cells that are modified such that they do not comprise LEDGF protein (LEDGF− cells),

ii) exposing the biological sample to mammalian cells that comprise the LEDGF protein (LEDGF+ cells), and

iii) comparing the amount of anti-LEDGF Abs bound to the LEDGF− cells to the amount of anti-LEDGF Abs bound to the LEDGF+ cells,

wherein determining a greater amount of anti-LEDGF Abs bound to the LEDGF+ cells relative to the amount of anti-LEDGF Abs bound to the LEDGF− cells is indicative that the biological sample comprised the anti-LEDGF Abs, and

wherein the same or less anti-LEDGF Abs bound to the LEDGF+ cells relative to the amount of anti-LEDGF Abs bound to the LEDGF− cells is indicative that the biological sample did not comprise the anti-LEDGF Abs.

11 . The method of claim 10 wherein the LEDGF− cells are killed and permeabilized and are immobilized on a solid substrate.

12 . The method of claim 11 , wherein the LEDGF+ cells are killed and permeabilized, and are immobilized on the same solid substrate as the LEDGF− cells, or are immobilized on a distinct solid substrate.

13 . The method of claim 12 , wherein the determining the amount of anti-LEDGF Abs is performed using an indirect immunofluorescence (IIF) assay.

14 . The method of claim 10 , wherein a chromosome in the LEDGF− cells comprises a Cas9 DNA coding sequence, or a DNA sequence encoding a clustered regularly interspaced short palindromic repeats (CRISPR) guide RNA targeted to a DNA sequence encoding the LEDGF protein, or a combination thereof.

15 . The method of claim 12 , wherein the LEDGF− and LEGDF+ cells are the same mammalian cell type.

16 - 20 . (canceled)

Assignments (2)
SECURITY AGREEMENT Recorded Jan 28, 2022
From: TRINITY BIOTECH, INC.; FITZGERALD INDUSTRIES INTERNATIONAL, INC.; CLARK LABORATORIES INC. (D/B/A TRINITY BIOTECH (USA)); BIOPOOL U.S., INC. (D/B/A TRINITY BIOTECH DISTRIBUTION); PRIMUS CORPORATION; IMMCO DIAGNOSTICS, INC.; MARDX DIAGNOSTICS, INC.
To: PERCEPTIVE CREDIT HOLDINGS III, LP
Reel/Frame 058890/0325 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 10, 2020
From: SURESH, LAKSHMANAN; MALYAVANTHAM, KISHORE
To: IMMCO DIAGNOSTICS, INC.
Reel/Frame 051477/0380 →